|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,684.00 DKK | -1.66% |
|
+2.59% | -16.92% |
| 12/05 | Nordea resumes coverage of Genmab with Buy rating and DKK 2,015 price target | FW |
| 11/05 | Deutsche Bank trims Genmab price target to DKK 2,250 (2,400), reiterates Buy | FW |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (USD) |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 8.24 | 14.56 | 10.17 | 10.91 | 8.1 | |||||
Return on Total Capital | 8.97 | 15.78 | 11.04 | 12.62 | 9.44 | |||||
Return On Equity % | 14.56 | 22.25 | 14.78 | 22.97 | 17.53 | |||||
Return on Common Equity | 14.56 | 22.25 | 14.78 | 22.97 | 17.53 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 100 | 100 | 98.63 | 95.42 | 93.6 | |||||
SG&A Margin | 15.13 | 18.34 | 20.01 | 17.61 | 16.83 | |||||
EBITDA Margin % | 38.5 | 46.04 | 33.76 | 34.33 | 34.68 | |||||
EBITA Margin % | 36.57 | 44.3 | 32.63 | 33.25 | 33.66 | |||||
EBIT Margin % | 35.58 | 43.82 | 32.3 | 32.89 | 33.6 | |||||
Income From Continuing Operations Margin % | 35.46 | 37.83 | 26.42 | 36.44 | 25.89 | |||||
Net Income Margin % | 35.46 | 37.83 | 26.42 | 36.44 | 25.89 | |||||
Net Avail. For Common Margin % | 35.46 | 37.83 | 26.42 | 36.44 | 25.89 | |||||
Normalized Net Income Margin | 34.43 | 33.11 | 20.27 | 26.98 | 22.24 | |||||
Levered Free Cash Flow Margin | 21.8 | 14.33 | 32.13 | 29.05 | 28.71 | |||||
Unlevered Free Cash Flow Margin | 21.9 | 14.42 | 32.24 | 29.39 | 29.74 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.37 | 0.53 | 0.5 | 0.53 | 0.39 | |||||
Fixed Assets Turnover | 9.91 | 12.71 | 11.12 | 12.19 | 13.65 | |||||
Receivables Turnover (Average Receivables) | 2.91 | 3.15 | 3.09 | 3.73 | 3.66 | |||||
Inventory Turnover (Average Inventory) | - | - | - | 16.55 | 17.63 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 14.5 | 15.57 | 13.34 | 5.25 | 2.02 | |||||
Quick Ratio | 14.5 | 15.57 | 13.32 | 5.24 | 2.01 | |||||
Operating Cash Flow to Current Liabilities | 1.42 | 2.15 | 2.97 | 1.46 | 0.83 | |||||
Days Sales Outstanding (Average Receivables) | 125.44 | 116 | 118.08 | 98.08 | 99.84 | |||||
Days Outstanding Inventory (Average Inventory) | - | - | - | 22.11 | 20.7 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 1.91 | 2.18 | 2.44 | 2.8 | 92.8 | |||||
Total Debt / Total Capital | 1.88 | 2.13 | 2.38 | 2.73 | 48.13 | |||||
LT Debt/Equity | 1.64 | 1.91 | 2.15 | 2.55 | 87.82 | |||||
Long-Term Debt / Total Capital | 1.6 | 1.87 | 2.1 | 2.48 | 45.55 | |||||
Total Liabilities / Total Assets | 9.87 | 9.37 | 10.43 | 19.89 | 54.58 | |||||
EBIT / Interest Expense | 232.15 | 304.52 | 197.07 | 58.99 | 20.49 | |||||
EBITDA / Interest Expense | 255.54 | 323.48 | 205.96 | 62.43 | 21.43 | |||||
(EBITDA - Capex) / Interest Expense | 236.15 | 308.38 | 192.41 | 60.88 | 20.82 | |||||
Total Debt / EBITDA | 0.13 | 0.09 | 0.14 | 0.14 | 4.15 | |||||
Net Debt / EBITDA | -5.69 | -3.2 | -4.92 | -2.68 | 2.84 | |||||
Total Debt / (EBITDA - Capex) | 0.14 | 0.09 | 0.15 | 0.14 | 4.27 | |||||
Net Debt / (EBITDA - Capex) | -6.16 | -3.36 | -5.27 | -2.75 | 2.92 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | -16.11 | 72.07 | 13.57 | 30.67 | 19.19 | |||||
Gross Profit, 1 Yr. Growth % | -16.11 | 72.07 | 12.02 | 26.42 | 16.92 | |||||
EBITDA, 1 Yr. Growth % | -50.25 | 105.73 | -14.72 | 33.66 | 22.62 | |||||
EBITA, 1 Yr. Growth % | -51.86 | 108.41 | -15.67 | 33.93 | 22.99 | |||||
EBIT, 1 Yr. Growth % | -52.36 | 111.9 | -15.61 | 33.04 | 23.15 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | -36.78 | 83.58 | -20.18 | 80.24 | -15 | |||||
Net Income, 1 Yr. Growth % | -36.78 | 83.58 | -20.18 | 80.24 | -15 | |||||
Normalized Net Income, 1 Yr. Growth % | -7.54 | 65.5 | -30.07 | 73.9 | 7.38 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | -36.93 | 83.68 | -20.06 | 83.82 | -12.32 | |||||
Accounts Receivable, 1 Yr. Growth % | 36.7 | 75.53 | -13.39 | 33.21 | 20.48 | |||||
Inventory, 1 Yr. Growth % | - | - | - | 8.77 | 100 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 32.47 | 35.59 | 24.13 | 15.23 | 5.66 | |||||
Total Assets, 1 Yr. Growth % | 16.48 | 22.95 | 17.17 | 29.82 | 100.7 | |||||
Tangible Book Value, 1 Yr. Growth % | 16.82 | 24.4 | 16.12 | -30.75 | -218.89 | |||||
Common Equity, 1 Yr. Growth % | 16.08 | 23.63 | 15.86 | 16.09 | 13.82 | |||||
Cash From Operations, 1 Yr. Growth % | -65.37 | 75.58 | 88.65 | 5.3 | 5.33 | |||||
Capital Expenditures, 1 Yr. Growth % | -17.92 | 25.79 | 15.46 | -48.91 | 37.04 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -60.57 | 13.12 | 163.04 | 17.48 | 16.72 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -60.45 | 13.33 | 162.17 | 17.92 | 19.42 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 25.73 | 20.14 | 39.9 | 21.82 | 24.76 | |||||
Gross Profit, 2 Yr. CAGR % | 25.73 | 20.14 | 38.94 | 19 | 21.54 | |||||
EBITDA, 2 Yr. CAGR % | 8.45 | 1.34 | 32.93 | 6.18 | 26.83 | |||||
EBITA, 2 Yr. CAGR % | 6.46 | 0.33 | 33.05 | 5.69 | 27.1 | |||||
EBIT, 2 Yr. CAGR % | 6.96 | 0.65 | 34.23 | 6.28 | 27.25 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 17.84 | 7.73 | 21.32 | 19.95 | 23.54 | |||||
Net Income, 2 Yr. CAGR % | 17.84 | 7.73 | 21.32 | 19.95 | 23.54 | |||||
Normalized Net Income, 2 Yr. CAGR % | 28.04 | 23.97 | 7.7 | 10.56 | 25.7 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 15.68 | 7.63 | 21.44 | 21.22 | 26.66 | |||||
Accounts Receivable, 2 Yr. CAGR % | 6.12 | 54.9 | 21.21 | 7.41 | 23.17 | |||||
Inventory, 2 Yr. CAGR % | - | - | - | - | 50 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 53.46 | 34.02 | 29.73 | 19.6 | 7.12 | |||||
Total Assets, 2 Yr. CAGR % | 27.52 | 19.67 | 19.71 | 23.33 | 56.86 | |||||
Tangible Book Value, 2 Yr. CAGR % | 27.12 | 20.55 | 19.83 | -10.33 | -11.84 | |||||
Common Equity, 2 Yr. CAGR % | 25.7 | 19.8 | 19.34 | 15.98 | 11.69 | |||||
Cash From Operations, 2 Yr. CAGR % | 29.62 | -22.02 | 82 | 40.94 | 5.23 | |||||
Capital Expenditures, 2 Yr. CAGR % | 78.6 | 1.62 | 20.51 | -23.19 | -16.45 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 68.36 | -33.11 | 76.54 | 71.59 | 17.18 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 68.16 | -32.95 | 76.4 | 71.64 | 18.77 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 41.01 | 39.59 | 17.67 | 36.75 | 17.72 | |||||
Gross Profit, 3 Yr. CAGR % | 41.01 | 39.59 | 17.13 | 34.63 | 15.15 | |||||
EBITDA, 3 Yr. CAGR % | 30.55 | 34.25 | -5.28 | 32.92 | 7.77 | |||||
EBITA, 3 Yr. CAGR % | 29.15 | 33.18 | -5.75 | 33.07 | 7.52 | |||||
EBIT, 3 Yr. CAGR % | 29.8 | 34.33 | -5.54 | 33.83 | 8.26 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 26.9 | 36.61 | -2.93 | 38.43 | 3.96 | |||||
Net Income, 3 Yr. CAGR % | 26.9 | 36.61 | -2.93 | 38.43 | 3.96 | |||||
Normalized Net Income, 3 Yr. CAGR % | 42.25 | 39.47 | 2.03 | 26.35 | 3.47 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 24.27 | 34.96 | -2.94 | 39.43 | 5.78 | |||||
Accounts Receivable, 3 Yr. CAGR % | 36.39 | 25.5 | 26.17 | 25.09 | 7.39 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 81.9 | 47.26 | 30.64 | 24.71 | 10.45 | |||||
Total Assets, 3 Yr. CAGR % | 42.78 | 25.98 | 18.62 | 22.99 | 39.57 | |||||
Tangible Book Value, 3 Yr. CAGR % | 42.74 | 26.21 | 18.82 | -0.19 | -5.23 | |||||
Common Equity, 3 Yr. CAGR % | 40.43 | 25.01 | 18.24 | 18.25 | 10.88 | |||||
Cash From Operations, 3 Yr. CAGR % | 29.96 | 43.42 | 4.68 | 51.65 | 24.47 | |||||
Capital Expenditures, 3 Yr. CAGR % | 51.83 | 58.91 | 6.03 | -9.47 | -9.45 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 471.03 | 47.46 | 4.23 | 54.4 | 47.35 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 471.86 | 47.44 | 4.29 | 54.77 | 48.52 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 36.1 | 43.9 | 40.35 | 32.03 | 18.54 | |||||
Gross Profit, 5 Yr. CAGR % | 36.1 | 43.9 | 39.96 | 30.8 | 16.98 | |||||
EBITDA, 5 Yr. CAGR % | 24.46 | 36.58 | 30.52 | 21.62 | 4.63 | |||||
EBITA, 5 Yr. CAGR % | 23.4 | 35.76 | 30.14 | 21.2 | 4.4 | |||||
EBIT, 5 Yr. CAGR % | 23.44 | 36.16 | 30.99 | 21.83 | 4.72 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 20.44 | 37.99 | 24.21 | 29.35 | 5.18 | |||||
Net Income, 5 Yr. CAGR % | 20.44 | 37.99 | 24.21 | 29.35 | 5.18 | |||||
Normalized Net Income, 5 Yr. CAGR % | 32.61 | 47.55 | 26.91 | 26.67 | 10.85 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 18.83 | 36.32 | 22.71 | 28.96 | 6.25 | |||||
Accounts Receivable, 5 Yr. CAGR % | 28.11 | 59.14 | 30.11 | 17.12 | 23.49 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 97.81 | 63.42 | 58.9 | 35.5 | 19.33 | |||||
Total Assets, 5 Yr. CAGR % | 36.28 | 35.61 | 33.06 | 24.78 | 31.1 | |||||
Tangible Book Value, 5 Yr. CAGR % | 36.41 | 34.73 | 33.1 | 9.95 | 4.22 | |||||
Common Equity, 5 Yr. CAGR % | 35.68 | 34.34 | 31.58 | 21.17 | 14.23 | |||||
Cash From Operations, 5 Yr. CAGR % | 46.72 | 19.74 | 48.7 | 42.43 | 3.24 | |||||
Capital Expenditures, 5 Yr. CAGR % | 83.07 | 29.07 | 38.43 | 18.81 | -5.18 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 85.22 | 12.87 | 251.04 | 57.15 | 7.76 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 85.44 | 12.98 | 251.26 | 57.31 | 8.49 |
- Stock Market
- Equities
- GMAB Stock
- Financials Genmab A/S
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















